The α1-Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 2, 2013, Pages 202-212

  O'Neil, Meghan L ^a   Beckwith, Lauren E ^a   Kincaid, Carrie L ^a   Rasmussen, Dennis D ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Education and Clinical Center   (United States)

Author keywords

Alcohol; Alcohol Preferring; Doxazosin; Noradrenergic; P Rats

Indexed keywords

ALCOHOL; DOXAZOSIN MESYLATE; WATER;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRINKING BEHAVIOR; FLUID INTAKE; FOOD INTAKE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT DURATION;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ALCOHOL DRINKING; ANIMALS; CHOICE BEHAVIOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; MALE; MOTOR ACTIVITY; RATS; RATS, INBRED STRAINS;

ANIMALIA; RATTUS;

EID: 84873264393     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2012.01884.x     Document Type: Article

References (48)

1. Abercrombie E, Keller R (1988) Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies. Neuroscience 27:897-904.
2. Amit Z, Brown ZW, Levitan DE, Ogren SO (1977) Noradrenergic mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition. Arch Int Pharmacodyn Ther 230:65-75.
3. Arencibia-Albite F, Paladini C, Williams JT, Jiménez-Rivera CA (2007) Noradrenergic modulation of the hyperpolarization-activated cation current (Ih) in dopamine neurons of the ventral tegmental area. Neuroscience 149:303-314.
4. Babamoto KS, Hirokawa WT (1992) Doxazosin: a new alpha 1-adrenergic antagonist. Clin Pharm 11:415-427.
5. Begleiter H, Porjesz B (1999) What is inherited in the predisposition toward alcoholism? A proposed model. Alcohol Clin Exp Res 23:1125-1135.
6. Bell RL, Rodd ZA, Lumeng L, Murphy JM, McBride WJ (2006) The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict Biol 11:270-288.
7. Brown ZW, Amit Z, Levitan DE, Ogren SO, Sutherland EA (1977) Noradrenergic mediation of the positive reinforcing properties of ethanol: II. Extinction of ethanol-drinking behavior in laboratory rats by inhibition of dopamine-beta-hydroxylase. Implications for treatment procedures in human alcoholics. Arch Int Pharmacodyn Ther 230:76-82.
8. Butler RW, Braff DL, Rausch JL, Jenkins MA, Sprock J, Geyer MA (1990) Physiological evidence of exaggerated startle response in a subgroup of Vietnam veterans with combat-related PTSD. Am J Psychiatry 147:1308-1312.
9. Cecchi M, Khoshbouei H, Javors M, Morilak D (2002) Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience 112:13-21.
10. Chester JA, Blose AM, Froehlich JC (2004) Acoustic startle reactivity during acute alcohol withdrawal in rats that differ in genetic predisposition toward alcohol drinking: effect of stimulus characteristics. Alcohol Clin Exp Res 28:677-687.
11. Cubeddu LX (1988) New alpha1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Am Heart J 116:133-162.
12. Davis WM, Smith SG, Werner TE (1978) Noradrenergic role in the self-administration of ethanol. Pharmacol Biochem Behav 9:369-374.
13. De Jong J, Wauben P, Huijbrechts I, Oolders H, Haffmans J (2010) Doxazosin treatment for posttraumatic stress disorder. J Clin Psychopharmacol 30:84-85.
14. Elliot HL, Meridith PA, Reid JL (1987) Pharmacokinetic overview of doxazosin. Am J Cardiol 59:78G-81G.
15. Evered MD (1990) Relationship between thirst and diazoxide-induced hypotension in rats. Am J Physiol Regul Integr Comp Physiol 259:R362-R370.
16. Finney JW, Hahn AC, Moos RH (1996) The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 91:1773-1796.
17. Garbutt JC (2009) The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 36:S15-S23.
18. Grossman S (1962) Direct adrenergic and cholinergic stimulation of hypothalamic mechanisms. Am J Physiol 202:872-882.
19. Guo TZ, Tinkienberg J, Oliker R, Maze M (1991) Central α1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an α2-adrenoceptor agonist. Anesthesiology 75:252-256.
20. Hamilton C, Reid J, Vincent J (1985) Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit. Br J Pharmacol 86:79-87.
21. Hasin DS, Stinson FS, Ogburn E, Grant BF (2007) Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 64:830-842.
22. Ikemoto S, Wise RA (2004) Mapping of chemical trigger zones for reward. Neuropharmacology 47:190-201.
23. Jaillon P (1980) Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 5:365-376.
24. Khoury AF, Kaplan NM (1991) α-Blocker therapy of hypertension. JAMA 266:394-398.
25. Kirby R, Andersen M, Gratzke P, Dahlstrand C, Høye K (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87:192-200.
26. Krystal JH, Webb E, Grillon C, Cooney N, Casal L, Morgan C III, Southwick SM, Davis M, Charney DS (1997) Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-chlorophenylpiperazine (mCPP). Psychopharmacology 131:207-215.
27. Lanteri C, Salomon L, Torrens Y, Glowinski J, Tassin JP (2007) Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology 33:1724-1734.
28. Lê A, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C, Shaham Y (2011) Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. Psychopharmacology 218:89-99.
29. Lê A, Harding S, Juzytsch W, Funk D, Shaham Y (2005) Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology 179:366-373.
30. Lê A, Quan B, Juzytch W, Fletcher P, Joharchi N, Shaham Y (1998) Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. Psychopharmacology 135:169-174.
31. Leggio L, Cardone S, Ferrulli A, Kenna GA, Dianna M, Swift RM, Addolorato G (2010) Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. Curr Pharm Des 16:2159-2186.
32. Menkes DB, Baraban JM, Aghajanian GK (1981) Prazosin selectively antagonizes neuronal responses mediated by α 1-adrenoceptors in brain. Naunyn Schmiedebergs Arch Pharmacol 317:273-275.
33. Meredith PA, Elliott HL, Kelman AW, Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modeling for the comparison of quinazoline α-adrenoceptor agonists in normotensive volunteers. J Cardiovasc Pharmacol 7:532-537.
34. Newton TF, De La Garza R II, Brown G, Kosten TR, Mahoney JJ III, Haile CN (2012) Noradrenergic α(1) receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS ONE 7:e30854.
35. Oryan S, Eidi M, Eidi A, Kohanrooz B (2003) Effects of α1-adrenoceptors and muscarinic cholinoceptors on water intake in rats. Eur J Pharmacol 477:123-127.
36. Paladini CA, Williams JT (2004) Noradrenergic inhibition of midbrain dopamine neurons. J Neurosci 24:4568-4575.
37. Prys-Roberts C, Farndon Jr. (2002) Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 26:1037-1042.
38. Rasmussen D, Burke B, Crites N (2005) Chronic daily ethanol and withdrawal: melatonin treatment reverses persistently increased acoustic startle response during abstinence. Alcohol Clin Exp Res 29:16A.
39. Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC (2009) The α1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 33:264-272.
40. Rogawski MA, Aghajanian GK (1982) Activation of lateral geniculate neurons by locus coeruleus or dorsal noradrenergic bundle stimulation: selective blockade by the alpha1-adrenoceptor antagonist prazosin. Brain Res 250:31-39.
41. Samokhvalov AV, Popova S, Room R, Ramonas M, Rehm J (2010) Disability associated with alcohol abuse and dependence. Alcohol Clin Exp Res 34:1871-1878.
42. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33:255-263.
43. Stevens D, McCarley R, Greene R (1994) The mechanism of noradrenergic alpha 1 excitatory modulation of pontine reticular formation neurons. J Neurosci 14:6481-6487.
44. Swift R, Oslin DW, Alexander M, Forman R (2011) Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 72:1012-1018.
45. Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C (2009) The economic impact of alcohol consumption: a systematic review. Subst Abuse Treat Prev Policy 4:20.
46. Vincent J, Elliott H, Meredith P, Reid J (1983) Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol 15:719-725.
47. Walker BM, Rasmussen DD, Raskind MA, Koob GF (2008) α1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 42:91-97.
48. Weiss RD (2004) Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 99:1382-1392.